Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Regeneron Pharmaceuticals is launching a Phase 2 clinical study titled ‘A Phase 2 Study to Investigate Ubamatamab With and Without REGN7075 in Treatment-Experienced Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC).’ The study aims to evaluate the effectiveness and safety of two drugs, ubamatamab and REGN7075, in treating advanced or metastatic NSCLC. Additionally, the study will assess the use of sarilumab to manage immune-related side effects associated with ubamatamab.
The intervention involves testing two main drugs, ubamatamab and REGN7075, both designed to treat NSCLC. Sarilumab is also being tested to mitigate potential immune-related side effects from ubamatamab.
This interventional study is randomized with a parallel assignment model, meaning participants are randomly assigned to different groups to receive the interventions. There is no masking involved, and the primary purpose is treatment-focused.
The study is set to begin on August 26, 2025, which is also the date of the last update. As of now, the study is not yet recruiting participants. The primary completion and estimated completion dates are not provided, but these will be crucial for tracking the study’s progress and results.
The market implications of this study are significant for Regeneron Pharmaceuticals, as positive outcomes could enhance their stock performance and investor confidence. The study’s focus on NSCLC, a major area of cancer research, places Regeneron in a competitive position within the pharmaceutical industry.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.